Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti HA1 T cell therapy - HighPassBio

Next Previous
Search
Drug Profile

Anti HA1 T cell therapy - HighPassBio

Alternative Names: HA-1 TCR CD8+ CD4+ Tm Cells; HA-1 TCR T Cells; HA1 TCR T cell therapy- HighPassBio; HA1-TCR2; TCR T cell immunotherapy - HighPassBio

Latest Information Update: 25 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ElevateBio; Fred Hutchinson Cancer Research Center
  • Developer Fred Hutchinson Cancer Research Center; National Cancer Institute (USA); The Leukemia & Lymphoma Society
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Leukaemia

Most Recent Events

  • 11 Jan 2023 HighPass Bio re-suspends a phase I trial in Leukaemia (In adolescents, In children, In the elderly, In infants, In neonates, Second-line therapy or greater, In adults) in USA (IV) due to funding issue (NCT03326921)
  • 28 Jun 2022 No recent reports of development identified for phase-I development in Leukaemia(In adolescents, In children, In the elderly, In infants, In neonates, Second-line therapy or greater, In adults) in USA (IV)
  • 20 May 2020 Fred Hutchinson Cancer Research Center in collaboration with National Cancer Institute reinitates a phase I trial in Leukaemia (In neonates, In infants, In childrens, In adults, In adolescents, In the elderly, Second-line therapy or greater) in USA (IV) (NCT03326921)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top